<DOC>
	<DOCNO>NCT00129116</DOCNO>
	<brief_summary>This study evaluate safety immunogenicity 3 formulation Hib-MenCY-TT vaccine 1 formulation Hib-MenC-TT vaccine compare control group receive license meningococcal serogroup C conjugate vaccine , administer 2 , 3 , 4 month age . Antibody persistence immune response booster vaccination additionally assess 12 18 month age .</brief_summary>
	<brief_title>3 Formulations Hib-MenCY-TT Vaccine &amp; 1 Formulation Hib-MenC-TT Vaccine Compared Licensed Meningococcal Serogroup C Conjugate Vaccine , Each Administered 2,3,4 Mths Age</brief_title>
	<detailed_description>Primary &amp; booster vaccination study evaluate immuno , reacto &amp; safety 3 diff . formulation GSKBio'combined Haemophilus influenzae typeb-meningococcal serogroups C &amp; Y-conjugate vaccine &amp; one formulation GSKBio ' Haemophilus influenzae typeb-meningococcal serogroup C conjugate vaccine give concomitantly With Infanrix penta ( DTaP-IPV-HepB vaccine ) , vs Meningitec meningococcal SerogroupC conj.vaccine ) give concomitantly With Infanrix hexa ( DTaP-IPV-HepB-Hib vaccine ) infant accord 2-3-4 mth schedule</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<criteria>Healthy infant without major congenital illness , immunosuppression , chronic disease bear 36 42 week gestation , 6 12 week age enrollment , vaccinate hepatitis B birth . Infants receive investigational drug , vaccine , chronic immunosuppressant , immunoglobulin blood product .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>12 Weeks</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Invasive bacterial disease cause Hib</keyword>
	<keyword>Neisseria meningitidis serogroups C &amp; Y</keyword>
</DOC>